We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 103.50 | 103.00 | 104.00 | 103.50 | 103.50 | 103.50 | 965 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 120.35 | 87.43M |
TIDMDXRX
RNS Number : 6787T
Diaceutics PLC
22 July 2020
Diaceutics PLC
("Diaceutics" or the "Group" or the "Company")
New contract win for DXRX platform
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces a significant new client contract win with a leading pharmaceutical company.
Diaceutics' will collaborate with this new client to produce an outsourced commercial solution for its US market, using the Company's new DXRX platform to improve patient testing and support the client's pioneering activities in the field of immunotherapy. This initial contract is worth $1.27 million.
The end-to-end diagnostic development and commercialisation service to be provided to this client evidences the evolution of Diaceutics' business model. The introduction of DXRX marks the shift from historical consulting and planned platform services to a broader client offering which brings together Diaceutics' propriety intellectual property, global laboratory network and repository of testing data on one proprietary platform, on a longer term basis. DXRX will enable the client to deliver seamless diagnostic testing for their precision medicine therapies which will result in greater efficiencies and drive increased testing rates and adoption.
Commenting on today's news, Peter Keeling, Diaceutics' Chief Executive said:
"This client win marks another milestone in the commercial success of Diaceutics. Our data and new commercialisation platform DXRX are designed to provide a full end-to-end service, and via these we believe we are well placed to significantly improve patient testing for our clients' therapy in this challenging cancer setting."
Enquiries:
Diaceutics PLC Stuart Hunt, Head of Investor Relations Tel: +44 (0)7815 778 536 Cenkos Securities PLC (Nomad & Broker) Tel: +44(0)20 7397 8900 Callum Davidson / Giles Balleny Michael Johnson (Sales) Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com Anna Dunphy Tel: +44 (0)7876 741 001 Paul McManus Tel: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Group, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CNTEAKXFAALEEFA
(END) Dow Jones Newswires
July 22, 2020 02:00 ET (06:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions